TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6365809
Drug: sfericase (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: sfericase (2 tablets, 3X/day)
Study: 30293937
Drug: Lipid-lowering drug
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering drug treatment (LLT)
Study: 30293937
Drug: Lipid-lowering drug
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering drug treatment (LLT) in highest risk tertile
Study: 23099111
Drug: Behavioral Weight-Loss-Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Weight-Loss-Treatment (BWLT)
Study: 17563981
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy plus basic therapy
Study: 11549652
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg oral conjugated E
Study: 11549652
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg droloxifene
Study: 28224367
Drug: MOC31PE immunotoxin
Normalized name: hepatitis B immunoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOC31PE immunotoxin administered intraperitoneally as a single dose after CRS-HIPEC with Mitomycin C
Study: 25319807
Drug: Adjuvant interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant interferon alfa-2b (IFN-α) therapy for 12 or 24 months
Study: 25128049
Drug: Sensor-augmented insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensor-augmented insulin pump therapy with Low Glucose Suspend (LGS)
Study: 25128049
Drug: Standard pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pump therapy with self-monitoring of blood glucose
Study: 25128049
Drug: Sensor-augmented insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensor-augmented insulin pump therapy with LGS
Study: 17560730
Drug: Mirtazapine monotherapy
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine monotherapy (n=13)
Study: 17560730
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with mirtazapine and lithium (n=13)
Study: 17560730
Drug: Mirtazapine monotherapy
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine monotherapy (n=10)
Study: 17560730
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with mirtazapine and carbamazepine (n=10)
Study: 10036794
Drug: 6% medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% medium molecular weight hydroxyethylstarch solution made of potato (K)
Study: 10036794
Drug: 6% medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% medium molecular weight hydroxyethylstarch solution made of corn (M)
Study: 25193374
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioural therapy (iCBT)
Study: 31638341
Drug: Cabazitaxel (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (20 mg/m2) i.v. every 3 weeks with prednisolone 10 mg daily orally, for a maximum of 10 cycles
Study: 26646596
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional therapies and care)
Study: 21195962
Drug: Intravenous conscious
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous conscious sedation
Study: 21195962
Drug: Oral analgesia
Normalized name: P-A-C Analgesic Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral analgesia
Study: 17156179
Drug: Vouchers for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vouchers for 6 months of methadone treatment
Study: 30860410
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both interventions
Study: 9849834
Drug: Selective digestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective digestive decontamination (SDD) with triple therapy of colimycin, tobramycin, and nystatin administered orally or via nasogastric tube every 6 hours, plus oropharyngeal decontamination with hexitidine for patients with mechanical ventilation or immune-depression.
Study: 17146635
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no SDD treatment)
Study: 8044943
Drug: recombinant tissue-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant tissue-type plasminogen activator (rTPA) therapy
Study: 30571923
Drug: Standardized rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized rehabilitation therapy
Study: 21477197
Drug: Combination training
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination training (non-verbal reasoning + working memory)
Study: 11938856
Drug: DMPS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPS plus Gandou tablet
Study: 8137583
Drug: Intraperitoneal distribution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal distribution imaging (IDI) using 1000 ml of normal saline and 1 mCi of Tc‐99m SC
Study: 30829771
Drug: Repeated onabotulinumtoxinA
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated onabotulinumtoxinA 64 U treatment in Period 2
Study: 30643391
Drug: Quesero XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quesero XR 200 mg
Study: 30643391
Drug: Seroquel XR
Normalized name: Seroquel XR
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Seroquel XR 200 mg
Study: 28366518
Drug: Conventional daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional daily gonadotropins (recombinant FSH and highly purified human menopausal gonadotrophin)
Study: 21585690
Drug: Decision aids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision aids for mastectomy versus breast-conserving therapy
Study: 19450071
Drug: Radiation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation treatment schedules
Study: 17008803
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with twice-daily IFN-beta (3X2=6 million units/day)
Study: 17008803
Drug: Consensus interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consensus interferon monotherapy
Study: 17008803
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with twice-daily IFN-beta
Study: 12933575
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) 3 mg/m2 with induction chemotherapy (DAT, DA, or FLAG-Ida)
Study: 12933575
Drug: GO 3
Normalized name: RESERVOIR,VGO 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: GO 3 mg/m2 with consolidation (MACE or HidAC)
Study: 24002913
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 100 mg
Study: 31233281
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg monotherapy
Study: 21351291
Drug: Multiple treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple treatments including Chinese herbs, acupuncture, and massage therapy
Study: 12233895
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy (omeprazole 20 mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid for 7 days)
Study: 12233895
Drug: Omeprazole alone
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole alone (20 mg once daily)
Study: 12233895
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori negative patients (omeprazole 20 mg once daily)
Study: 10081035
Drug: Fenofibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (200 mg daily for 2 weeks)
Study: 7752627
Drug: Alcohol session
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol session (0.625 g/kg body weight of 80-proof ethyl alcohol)
Study: 2268634
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of fluoride varnish (Duraphat) on cavity walls
Study: 6780021
Drug: Real bilateral
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real bilateral electric convulsion therapy
Study: 6780021
Drug: Simulated bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated bilateral electric convulsion therapy
Study: 6780021
Drug: Real bilateral
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real bilateral electric convulsion therapy after switching from simulated treatment
Study: 31815655
Drug: Chinese pediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese pediatric Tuina (15-25 min treatment once per day for 3 consecutive days)
Study: 31815655
Drug: Sham pediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham pediatric Tuina (15-25 min treatment once per day for 3 consecutive days)
Study: 28209636
Drug: Sodium-restricted diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-restricted diet (target <2 g sodium per day)
Study: 22691430
Drug: DTaP₅-IPV-Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP₅-IPV-Hib vaccine
Study: 19556533
Drug: Antiplatelet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet treatment (specifics not provided)
Study: 15632895
Drug: Glucose-Insulin-Potassium (GIK)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-Insulin-Potassium (GIK) intravenous infusion for 24 hours
Study: 15632895
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (Reviparin) injection twice daily for 7 days
Study: 15632895
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection twice daily for 7 days
Study: 7524736
Drug: nIFN alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: nIFN alpha (3 MU) intramuscularly three times weekly
Study: 7524736
Drug: nIFN alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: nIFN alpha (3 MU) intramuscularly three times weekly plus 6-methyl-prednisolone (16 mg/d orally on non-IFN days)
Study: 7524736
Drug: 6-methyl-prednisolone (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-methyl-prednisolone (16 mg/d orally) only
Study: 23582353
Drug: AREDS formulation
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AREDS formulation (high-dose antioxidants C, E, β-carotene, and zinc)
Study: 18180976
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg monthly oral ibandronate
Study: 18180976
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of ibandronate
Study: 14624185
Drug: Sertraline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline and CBT
Study: 10174220
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of photographic and written information
Study: 3034538
Drug: PDD 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDD 10 mg per day X 10, every 3 weeks (hepatic arterial perfusion)
Study: 3034538
Drug: 5‐Fu 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐Fu 250 mg per day X 4, every week and thio‐tepa (TSPA) 10 mg, twice a week (hepatic arterial perfusion)
Study: 3034538
Drug: PDD 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDD 20 mg per day X 5, every 3 weeks (intravenous chemotherapy)
Study: 3034538
Drug: 5‐Fu 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐Fu 500 mg and TSPA 10 mg, twice a week (intravenous chemotherapy)
Study: 3034538
Drug: Intravenous PDD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PDD
Study: 3034538
Drug: Intravenous control
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous control group
Study: 26667118
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive approach based on atraumatic restorative treatment (ART) procedures
Study: 23569175
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (GLA)
Study: 18093252
Drug: Coracten (encapsulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coracten (encapsulated mini-tablet)
Study: 18093252
Drug: N-GITS (30-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-GITS (30-mg osmotic, constant-release nifedipine gastrointestinal therapeutic system)
Study: 10475139
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg oral budesonide
Study: 8757005
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine (DHE) nasal spray (1 mg plus optional 1 mg)
Study: 7106687
Drug: Phlebodril (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebodril (fixed combination)
Study: 24982780
Drug: Trospium 60
Normalized name: trospium 60 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trospium 60 mg/day and Solifenacin 20 mg/day during two cycles (1.5 and 1 month with one month interval)
Study: 24982780
Drug: Trospium 60
Normalized name: trospium 60 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trospium 60 mg/day and Solifenacin 20 mg/day during one cycle therapy
Study: 19920098
Drug: Adenovirus/prostate-specific antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenovirus/prostate-specific antigen (PSA) vaccine
Study: 17214953
Drug: Concurrent verbal
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent verbal protocol method
Study: 17214953
Drug: Quantitative analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quantitative analysis of concurrent reports
Study: 7658483
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g calcium
Study: 7658483
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g calcium
Study: 21864622
Drug: 7.5-mcg or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5-mcg or 30-mcg of hemagglutinin intramuscularly
Study: 19644190
Drug: Lercamen (lercadipine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercamen (lercadipine) 10-20 mg
Study: 17905575
Drug: Budesonide/formoterol 160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 160/4.5 microg two inhalations twice daily and as needed
Study: 17905575
Drug: Salmeterol/fluticasone 50/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone 50/500 microg one inhalation twice daily plus terbutaline as needed
Study: 15388510
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg at week 0, 2, and 6)
Study: 9787699
Drug: High iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: High iron weaning diet (8.2 +/‐ 2.9 mg/day)
Study: 9787699
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group weaning diet (5.2 +/‐ 3.4 mg/day)
Study: 8925517
Drug: Weekly wine
Normalized name: Wine grape
DrugBank: Wine grape (DB10634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly wine consumption
Study: 2673511
Drug: Intravenous metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoprolol (15 mg) followed by oral metoprolol (200 mg daily for 15 days)
Study: 25417843
Drug: Trivia Game
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trivia Game (treatment group)
Study: 22047559
Drug: Anti-inhibitor coagulant
Normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inhibitor coagulant complex (AICC) prophylaxis at a target dose of 85 U/kg (±15%) on 3 nonconsecutive days per week
Study: 22047559
Drug: On-demand therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand therapy (AICC at a target dose of 85 U/kg [±15%] used for bleeding episodes)
Study: 19780298
Drug: Primary cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primary cisplatin-based intraperitoneal therapy
Study: 19780298
Drug: Intravenous cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisplatin-based treatment
Study: 10400014
Drug: Acetylsalicylate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylsalicylate (1 g IV) after bradykinin infusion into the iliac artery
Study: 10400014
Drug: Acetylsalicylate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylsalicylate (1 g IV) after bradykinin infusion into the left coronary artery
Study: 2100324
Drug: Ranitidine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 50 mg i.v.
Study: 2100324
Drug: Ranitidine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 50 mg i.v. and metoclopramide, 10 mg i.v.
Study: 7369098
Drug: Prajmalium bitartrate
Normalized name: prajmalium bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prajmalium bitartrate (60 mg orally, 20 mg every 4 hours)
Study: 7369098
Drug: Lidocaine (2.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (2.1 mg/minute infusion, daily dose of 3 g)
Study: 7369098
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antiarrhythmic drug)
Study: 28202358
Drug: Lipotoxin (onabotulinumtoxinA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipotoxin (onabotulinumtoxinA 200 U with 80 mg sphingomyelin)
Study: 22131602
Drug: Home-based evaluation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based evaluation and treatment of OSA
Study: 22131602
Drug: Lab-based evaluation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lab-based evaluation and treatment of OSA
Study: 9564987
Drug: Salbutamol/nedocromil combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol/nedocromil combination (200 microg/4 mg)
Study: 30265816
Drug: Fluticasone Furoate/Umeclidinium/Vilanterol
Normalized name: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) 100 µg/62.5 µg/25 µg
Study: 30265816
Drug: Budesonide/Formoterol (BUD/FOR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/Formoterol (BUD/FOR) 400 µg/12 µg
Study: 24841018
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of pre-operative antibiotics
Study: 9000193
Drug: Standard-dose polyagent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose polyagent self‐administered intracavernous pharmacotherapy
Study: 9000193
Drug: High-dose polyagent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose polyagent self‐administered intracavernous pharmacotherapy
Study: 29133566
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg iclaprim administered as a 2-h infusion every 12 h
Study: 29133566
Drug: 0.8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg/kg iclaprim infused intravenously over 0.5 h every 12 h (previous regimen)
Study: 23149085
Drug: Gastroretentive gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastroretentive gabapentin (G‐GR) 1800mg
Study: 20494655
Drug: Intracoronary delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary delivery of abciximab (0.25 mg/kg)
Study: 20494655
Drug: Intravenous delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous delivery of abciximab (0.25 mg/kg)
Study: 20494655
Drug: High-dose abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose abciximab (>=0.30 mg/kg)
Study: 20494655
Drug: Standard-dose abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose abciximab (0.25 mg/kg)
Study: 20494655
Drug: High-dose abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose abciximab
Study: 15689724
Drug: Skills-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skills-based treatment protocol
Study: 15689724
Drug: Supportive relationship
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive relationship therapy
Study: 2052467
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg daily plus hydrochlorothiazide 25 mg daily
Study: 6137785
Drug: Lormetazepam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam (0.5 mg)
Study: 30975106
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (high intervention dose)
Study: 25293966
Drug: Metacognitive detached
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive detached mindfulness therapy
Study: 25058771
Drug: Lichtenstein technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lichtenstein technique (group L)
Study: 15665959
Drug: Refracterin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refracterin therapy
Study: 9129897
Drug: Intravenous digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous digoxin (mean dose 0.88 ± 0.35 mg)
Study: 9129897
Drug: Placebo (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mean dose 0.96 ± 0.37 mg)